Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
OMIC Stock Summary
Top 10 Correlated ETFs
OMIC
In the News
Singular Genomics to Report Fourth Quarter and Full Year 2023 Financial Results on March 18, 2024
SAN DIEGO, March 04, 2024 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2023 after the market close on Monday, March 18, 2024. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Singular Genomics Systems, Inc. (OMIC) Q3 2023 Earnings Call Transcript
Singular Genomics Systems, Inc. (NASDAQ:OMIC ) Q3 2023 Earnings Conference Call November 14, 2023 4:30 PM ET Company Participants Philip Taylor - IR Drew Spaventa - CEO, Founder & Chairman Dalen Meeter - CFO Conference Call Participants Dan Brennan - TD Cowen Matt Sykes - Goldman Sachs John Sourbeer - UBS Operator Greetings. Welcome to the Singular Genomics Systems, Inc. Third Quarter 2023 Earnings Conference Call.
Singular Genomics to Report Third Quarter 2023 Financial Results on November 14, 2023
SAN DIEGO, Oct. 24, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced that it will report financial results for the third quarter 2023 after the market close on Tuesday, November 14, 2023. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Beware! 3 Biotech Stocks Waving Massive Red Flags Right Now
The biotech sector never fails to offer up stocks full of massive issues at any given time. Developing novel therapeutic devices and pharmaceuticals is, after all, very expensive.
Singular Genomics to Present at the Gilmartin Group Emerging Growth Company Showcase
SAN DIEGO, Sept. 08, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced plans to participate in the virtual Gilmartin Group Emerging Growth Company Showcase.
Singular Genomics Systems, Inc. (OMIC) Q2 2023 Earnings Call Transcript
Singular Genomics Systems, Inc. (NASDAQ:OMIC ) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Philip Taylor - IR Drew Spaventa - Founder, Chair and CEO Dalen Meeter - CFO Conference Call Participants Matt Sykes - Goldman Sachs Dan Brennan - TD Cowen Operator Good day, everyone, and welcome to the Singular Genomics Systems, Inc. Second Quarter 2023 Earnings Conference Call. At this time, all participants have been placed on a listen-only mode, and we will open the floor for your questions and comments after the presentation.
Singular Genomics to Report Second Quarter 2023 Financial Results on August 9, 2023
SAN DIEGO, July 26, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced that it will report financial results for the second quarter 2023 after the market close on Wednesday, August 9, 2023. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.
Singular Genomics to Present at the Goldman Sachs Global Healthcare Conference
SAN DIEGO, June 01, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced plans to present at the Goldman Sachs 44th Annual Global Healthcare Conference in Dana Point, CA.
Singular Genomics Systems, Inc. (OMIC) Q1 2023 Earnings Call Transcript
Singular Genomics Systems, Inc. (NASDAQ:OMIC ) Q1 2023 Results Conference Call May 9, 2023 4:30 PM ET Company Participants Philip Taylor - IR Drew Spaventa - Founder and CEO Dalen Meeter - CFO Conference Call Participants Tom Stevens - TD Cowen John Sourbeer - UBS Michael Ryskin - Bank of America Operator Greetings. Welcome to the Singular Genomics Systems, Incorporated First Quarter 2023 Earnings Conference Call.
Similar Genomics Systems (OMIC) Reports Q1 Loss, Lags Revenue Estimates
Similar Genomics Systems (OMIC) came out with a quarterly loss of $0.33 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.31 per share a year ago.
OMIC Financial details
OMIC Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0 | 0.01 | 0.04 | |
Net income per share | -0.25 | -0.41 | -2.1 | -1.24 | -1.3 | |
Operating cash flow per share | -0.23 | -0.36 | -1.1 | -1.22 | -1.01 | |
Free cash flow per share | -0.25 | -0.38 | -1.2 | -1.31 | -1.03 | |
Cash per share | 0.94 | 0.39 | 7.21 | 3.44 | 2.39 | |
Book value per share | -0.5 | -0.74 | 7.15 | 3.66 | 2.46 | |
Tangible book value per share | -0.5 | -0.74 | 7.15 | 3.66 | 2.46 | |
Share holders equity per share | -0.5 | -0.74 | 7.15 | 3.66 | 2.46 | |
Interest debt per share | 0.05 | 0.15 | 0.23 | 0.84 | 1.05 | |
Market cap | 1.27B | 1.78B | 543.59M | 143.01M | 33.49M | |
Enterprise value | 1.27B | 1.78B | 352.44M | 127.59M | 92.55M | |
P/E ratio | -102.96 | -62.2 | -5.5 | -1.62 | -0.35 | |
Price to sales ratio | 0 | 0 | 0 | 186.94 | 11.51 | |
POCF ratio | -111.47 | -71.68 | -10.51 | -1.64 | -0.45 | |
PFCF ratio | -104.16 | -67.91 | -9.61 | -1.54 | -0.45 | |
P/B Ratio | -51.39 | -34.58 | 1.62 | 0.55 | 0.19 | |
PTB ratio | -51.39 | -34.58 | 1.62 | 0.55 | 0.19 | |
EV to sales | 0 | 0 | 0 | 166.78 | 31.79 | |
Enterprise value over EBITDA | -106.01 | -67.47 | -5.82 | -1.42 | -1.07 | |
EV to operating cash flow | -111.2 | -71.58 | -6.82 | -1.46 | -1.26 | |
EV to free cash flow | -103.9 | -67.82 | -6.23 | -1.37 | -1.24 | |
Earnings yield | -0.01 | -0.02 | -0.18 | -0.62 | -2.83 | |
Free cash flow yield | -0.01 | -0.01 | -0.1 | -0.65 | -2.23 | |
Debt to equity | -0.1 | -0.18 | 0.03 | 0.23 | 0.42 | |
Debt to assets | 0.05 | 0.31 | 0.03 | 0.18 | 0.28 | |
Net debt to EBITDA | 0.26 | 0.09 | 3.16 | 0.17 | -0.68 | |
Current ratio | 41.78 | 7.47 | 51.57 | 19.01 | 10.51 | |
Interest coverage | -751.18 | -38.35 | -72.43 | -122.53 | -93.37 | |
Income quality | 0.92 | 0.89 | 0.52 | 0.96 | 0.78 | |
Dividend Yield | 0 | 0 | 0.01 | 0 | 0 | |
Payout ratio | -0.2 | -0.26 | -0.04 | 0 | 0 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 60.39 | 16.41 | |
Intangibles to total assets | 0 | 0 | 0 | -0.05 | -0.06 | |
Capex to operating cash flow | 0.07 | 0.06 | 0.09 | 0.07 | 0.01 | |
Capex to revenue | 0 | 0 | 0 | -7.87 | -0.33 | |
Capex to depreciation | -2.29 | -2.16 | -4.29 | -1 | -0.13 | |
Stock based compensation to revenue | 0 | 0 | 0 | 17.87 | 3.92 | |
Graham number | 1.68 | 2.63 | 18.39 | 10.11 | 8.49 | |
ROIC | 0.57 | 0.67 | -0.18 | -0.25 | -0.35 | |
Return on tangible assets | -0.26 | -0.94 | -0.28 | -0.26 | -0.34 | |
Graham Net | -0.54 | -0.8 | 6.85 | 2.62 | 1.31 | |
Working capital | 45.35M | 23.88M | 341.02M | 254.31M | 173.94M | |
Tangible asset value | -24.73M | -51.56M | 336.17M | 275.18M | 195.33M | |
Net current asset value | -26.44M | -54.49M | 328.29M | 200.78M | 105.77M | |
Invested capital | -0.1 | -0.18 | 0.03 | 0.23 | 0.42 | |
Average receivables | 0 | 8.5K | 533.5K | 981.5K | 1.25M | |
Average payables | 0 | 494K | 1.39M | 2.72M | 2.84M | |
Average inventory | 0 | -8.5K | 1.5M | 10.62M | 15.9M | |
Days sales outstanding | 0 | 0 | 0 | 435.61 | 198.61 | |
Days payables outstanding | 585.04 | 243.9 | 756.42 | 1.43K | 272.2 | |
Days of inventory on hand | 0 | -9.71 | 970 | 8.43K | 1.43K | |
Receivables turnover | 0 | 0 | 0 | 0.84 | 1.84 | |
Payables turnover | 0.62 | 1.5 | 0.48 | 0.25 | 1.34 | |
Inventory turnover | 0 | -37.59 | 0.38 | 0.04 | 0.26 | |
ROE | 0.5 | 0.56 | -0.29 | -0.34 | -0.53 | |
Capex per share | -0.02 | -0.02 | -0.1 | -0.08 | -0.01 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |
Net income per share | -0.27 | -0.31 | -0.35 | -0.31 | -0.32 | |
Operating cash flow per share | -0.28 | -0.25 | -0.28 | -0.23 | -0.26 | |
Free cash flow per share | -0.3 | -0.25 | -0.28 | -0.23 | -0.26 | |
Cash per share | 3.42 | 3.14 | 2.85 | 2.61 | 2.36 | |
Book value per share | 3.64 | 3.34 | 3.01 | 2.72 | 2.43 | |
Tangible book value per share | 3.64 | 3.34 | 3.01 | 2.72 | 2.43 | |
Share holders equity per share | 3.64 | 3.34 | 3.01 | 2.72 | 2.43 | |
Interest debt per share | 0.83 | 0.82 | 0.81 | 1.06 | 1.03 | |
Market cap | 143.89M | 87.03M | 60.18M | 27.88M | 33.84M | |
Enterprise value | 128.46M | 16.35M | 43.76M | 71.59M | 92.9M | |
P/E ratio | -1.83 | -0.98 | -0.59 | -0.31 | -0.36 | |
Price to sales ratio | 188.09 | 100.85 | 119.17 | 60.35 | 31.31 | |
POCF ratio | -7.22 | -4.85 | -3.01 | -1.66 | -1.79 | |
PFCF ratio | -6.62 | -4.81 | -2.96 | -1.65 | -1.75 | |
P/B Ratio | 0.55 | 0.36 | 0.28 | 0.14 | 0.19 | |
PTB ratio | 0.55 | 0.36 | 0.28 | 0.14 | 0.19 | |
EV to sales | 167.93 | 18.95 | 86.65 | 154.95 | 85.93 | |
Enterprise value over EBITDA | -6.16 | -0.76 | -1.87 | -3.54 | -4.36 | |
EV to operating cash flow | -6.45 | -0.91 | -2.19 | -4.26 | -4.91 | |
EV to free cash flow | -5.91 | -0.9 | -2.16 | -4.23 | -4.81 | |
Earnings yield | -0.14 | -0.25 | -0.43 | -0.8 | -0.69 | |
Free cash flow yield | -0.15 | -0.21 | -0.34 | -0.61 | -0.57 | |
Debt to equity | 0.23 | 0.24 | 0.27 | 0.39 | 0.42 | |
Debt to assets | 0.18 | 0.19 | 0.21 | 0.27 | 0.28 | |
Net debt to EBITDA | 0.74 | 3.28 | 0.7 | -2.16 | -2.77 | |
Current ratio | 19.01 | 19.73 | 16.18 | 13.64 | 10.51 | |
Interest coverage | -92.72 | -97.98 | -102.23 | -86.1 | -88.09 | |
Income quality | 0.94 | 0.76 | 0.78 | 0.75 | 0.81 | |
Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
Payout ratio | -0.02 | 0 | 0 | 0 | 0 | |
Sales general and administrative to revenue | 30.79 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 14.07 | 14.17 | 25 | 24.29 | 10.81 | |
Intangibles to total assets | -0.05 | 0 | 0 | 0 | -0.06 | |
Capex to operating cash flow | 0.09 | 0.01 | 0.02 | 0.01 | 0.02 | |
Capex to revenue | -2.38 | -0.19 | -0.61 | -0.24 | -0.36 | |
Capex to depreciation | -1.06 | -0.09 | -0.16 | -0.06 | -0.24 | |
Stock based compensation to revenue | 4.05 | 3.57 | 5.63 | 6.05 | 2.49 | |
Graham number | 4.74 | 4.81 | 4.89 | 4.32 | 4.16 | |
ROIC | -0.06 | -0.07 | -0.09 | -0.08 | -0.09 | |
Return on tangible assets | -0.06 | -0.07 | -0.09 | -0.08 | -0.08 | |
Graham Net | 2.61 | 2.36 | 2.05 | 1.56 | 1.3 | |
Working capital | 254.31M | 233.98M | 211.74M | 195.34M | 173.94M | |
Tangible asset value | 275.18M | 240.33M | 218.39M | 199.03M | 195.33M | |
Net current asset value | 200.78M | 181.33M | 160.1M | 125.3M | 105.77M | |
Invested capital | 0.23 | 0.24 | 0.27 | 0.39 | 0.42 | |
Average receivables | 891K | 779.5K | 671.5K | 2.01M | 2.46M | |
Average payables | 3.04M | 2.54M | 1.98M | 2.2M | 2.51M | |
Average inventory | 17.46M | 17.69M | 15.76M | 13.89M | 13.5M | |
Days sales outstanding | 107.41 | 67.37 | 124.22 | 648.9 | 131.88 | |
Days payables outstanding | 353.5 | 220.48 | 297.59 | 415.33 | 151.38 | |
Days of inventory on hand | 2.08K | 1.91K | 2.16K | 2.29K | 794.2 | |
Receivables turnover | 0.84 | 1.34 | 0.72 | 0.14 | 0.68 | |
Payables turnover | 0.25 | 0.41 | 0.3 | 0.22 | 0.59 | |
Inventory turnover | 0.04 | 0.05 | 0.04 | 0.04 | 0.11 | |
ROE | -0.08 | -0.09 | -0.12 | -0.11 | -0.13 | |
Capex per share | -0.03 | 0 | 0 | 0 | -0.01 |
OMIC Frequently Asked Questions
What is Singular Genomics Systems, Inc. stock symbol ?
Singular Genomics Systems, Inc. is a US stock , located in La jolla of Ca and trading under the symbol OMIC
What is Singular Genomics Systems, Inc. stock quote today ?
Singular Genomics Systems, Inc. stock price is $0.5142 today.
Is Singular Genomics Systems, Inc. stock public?
Yes, Singular Genomics Systems, Inc. is a publicly traded company.